Protein Therapeutics Market Intelligence Report Offers Insights on Growth Prospects 2022–2028
The protein therapeutics market was estimated at US$ 117.4 Billion in 2021 and is expected to grow at a CAGR of 7.06% during 2022-2028 to reach US$ 190.1 Billion in 2028.
Protein therapeutics refer to drugs that are designed using proteins and other biomolecules to treat diseases and disorders. They are a rapidly growing class of drugs and have become an essential part of the pharmaceutical industry. The protein therapeutics market has seen significant growth in recent years, driven by factors such as increasing prevalence of chronic diseases, technological advancements, and growing demand for personalized medicine. The protein therapeutics market was estimated at US$ 117.4 Billion in 2021 and is expected to grow at a CAGR of 7.06% during 2022-2028 to reach US$ 190.1 Billion in 2028.
This growth can be attributed to the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, which require long-term treatment and management. Protein therapeutics have proven to be effective in treating these diseases and offer several advantages over traditional small molecule drugs, including higher specificity, fewer side effects, and better patient outcomes.
Another factor contributing to the growth of the protein therapeutics market is the increasing demand for personalized medicine. Protein therapeutics can be customized to target specific disease pathways or genetic mutations, allowing for more precise and effective treatment. This has led to the development of a new generation of protein therapeutics, including antibody-drug conjugates, bispecific antibodies, and fusion proteins, which are designed to target specific cells or tissues and improve treatment outcomes.
Request a sample here:
https://www.stratviewresearch.com/Request-Sample/3183/protein-therapeutics-market.html#form
Recent technological advancements in protein engineering and biomanufacturing have also contributed to the growth of the protein therapeutics market. The development of new technologies such as CRISPR-Cas9 gene editing, protein display platforms, and high-throughput screening methods have enabled researchers to design and produce new protein therapeutics more quickly and efficiently than ever before. In addition, improvements in biomanufacturing processes, such as single-use bioreactors and continuous bioprocessing, have led to increased production efficiency and reduced costs.
However, the protein therapeutics market also faces several challenges. One of the main challenges is the high cost of development and production. Protein therapeutics are complex and costly to develop, and the manufacturing process can be challenging due to the need for strict quality control measures. This has resulted in high drug prices, which can limit access to treatment for some patients.
In 2021, North America held the largest worldwide market share for protein therapeutics, and it is expected to hold this position throughout the forecast period. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. However, due to an increase in R&D efforts, an increase in disposable incomes, and a rise in patient awareness of protein therapies, the Asia-Pacific region is expected to experience significant growth. India and China are additionally anticipated to see rapid CAGR growth in the Asia-Pacific protein therapeutics market.
Key Players
The following are the major players in the protein therapeutics market:
- Amgen Inc.
- Abbott
- Abbvie Inc.
- Baxter International Inc.
- Pfizer Inc
- Novo Nordisk A/S
- Merck & Co. Inc.
- Biogen Inc.
- Csl Behring L.L.C.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnson
In conclusion, the protein therapeutics market is a rapidly growing segment of the pharmaceutical industry, driven by factors such as increasing prevalence of chronic diseases, demand for personalized medicine, and technological advancements in protein engineering and biomanufacturing. While the market faces challenges such as high development and production costs, the potential benefits of protein therapeutics make them an essential tool for the treatment of a wide range of diseases and disorders.